Date: October 28, 2026

Financial Performance Summary

Quarterly Performance (₹ in Million)

  • Revenue from Operations: Q2FY27: ₹920.9 vs Q1FY27: ₹749.8 vs Q2FY26: ₹1,214.8 (YoY decline of 24.2%)
  • EBITDA: Q2FY27: ₹155.7 vs Q1FY27: ₹74.1 vs Q2FY26: ₹332.5 (YoY decline of 53.2%)
  • EBITDA Margin (%): Q2FY27: 16.0% vs Q1FY27: 9.5% vs Q2FY26: 26.8% (YoY margin contraction of 10.8 percentage points)
  • Reported Profit After Tax: Q2FY27: ₹150.2 vs Q1FY27: ₹42.1 vs Q2FY26: ₹281.1 (YoY decline of 46.6%)
  • PAT Margin (%): Q2FY27: 16.3% vs Q1FY27: 5.6% vs Q2FY26: 23.1% (YoY margin contraction of 6.8 percentage points)
  • EPS in Rs.: Q2FY27: 3.38 vs Q1FY27: 0.95 vs Q2FY26: 8.68 (YoY decline of 61.1%)

Half-Yearly Performance (₹ in Million)

  • Revenue from Operations: H1FY27: ₹1,670.7 vs H1FY26: ₹1,894.9 (YoY decline of 11.8%)
  • EBITDA: H1FY27: ₹229.8 vs H1FY26: ₹279.8 (YoY decline of 17.9%)
  • EBITDA Margin (%): H1FY27: 13.1% vs H1FY26: 14.5% (YoY margin contraction of 1.4 percentage points)
  • Reported Profit After Tax: H1FY27: ₹192.4 vs H1FY26: ₹219.8 (YoY decline of 12.5%)
  • PAT Margin (%): H1FY27: 11.5% vs H1FY26: 11.6% (margin largely stable)
  • EPS in Rs.: H1FY27: 4.33 vs H1FY26: 6.79 (YoY decline of 36.2%)

Performance Drivers & Challenges

Margin Pressure Factors

  • Higher freight and logistics costs due to shipping rate escalation, mitigated by route re-routing, air uplift and war-risk surcharges
  • Exceptional and non-recurring costs arising from enhanced site security, protective measures, standby and idle time, and extended project preliminaries impacting H1FY27 profitability
  • Higher raw material costs on a major reference vaccine project
  • The company notes these exceptional costs are not expected to recur at the same level in H2

Operational Highlights

  • The business enters H2 FY27 with its strongest execution runway of the year, with bulk of planned execution falling in this half
  • Maximum orders/projects are covered with Letters of Credit (LCs), minimizing receivable risk
  • UAE operations demonstrated strong order traction in Q2 FY27 despite regional challenges, with installation continuing under enhanced security and protective measures
  • Africa initiatives are gaining momentum, including solutions for cell and gene therapy (CGT) and other advanced-technology facility projects
  • Company navigated geopolitical uncertainty and freight volatility across GCC markets while maintaining continuity of operations, deliveries and customer commitments despite higher costs

Order Book & Growth Outlook

Current Order Position

  • Healthy Order Book of approximately ₹900 Crore
  • Additional prospective orders from Africa and Saudi Arabia under discussion: ₹800-850 Crore
  • The existing order position provides meaningful visibility over the next 12 months
  • Deferred orders have been delayed in timing, with no cancellations recorded and customer engagement remaining active

Future Outlook

  • Company is confident of achieving its FY27 operational PAT margin objective of 8-9%
  • Revenue and profitability are expected to step up in H2 as project milestones are delivered
  • The company has executed 750+ projects across 62 countries, supported by a global workforce of 650+ professionals
  • Regional operations span UAE, Saudi Arabia, Egypt, Nigeria, UK, Algeria and Sri Lanka

Business Overview

Fabtech Technologies Limited is a pharmaceutical engineering company providing specialised engineering, technology and turnkey solutions (including Design & Build) to the pharmaceutical, biotechnology and healthcare sectors. Capabilities include project design, technology transfer, pharmaceutical equipment manufacturing, turnkey project management, cleanroom infrastructure, cleanroom partitions and HVAC, containment solutions, pharmaceutical MEP, clean utilities, process piping, purified water systems and water-for injection systems.